.jpg)
OncoGuard Liquid Biopsy
OncoGuard Liquid Biopsy is a non-invasive molecular profiling platform based on next-generation sequencing (NGS) of circulating tumor DNA (ctDNA) from blood samples. By analyzing a carefully designed panel of clinically relevant genes and fusions, the test provides a real-time, patient-specific molecular profile of advanced solid tumors (such as lung, colorectal, and breast cancer), enabling precise prognostic assessment and personalized therapy selection.
OncoGuard Liquid Biopsy is designed as a routine clinical tool for precision oncology, allowing physicians to determine and continuously update the molecular profile of a patient’s tumor from a simple blood draw. It supports therapy selection and modulation in advanced cancer by identifying actionable mutations, mechanisms of resistance, and minimal residual disease without the need for repeated invasive tissue biopsies. This can improve treatment efficacy, reduce time to appropriate therapy, and enhance quality of life for patients. The platform can be used in translational research and clinical trials to monitor tumor evolution, study intratumoral heterogeneity, and evaluate treatment response dynamics in real time. Aggregated ctDNA data can also contribute to the discovery of new therapeutic targets and to the optimization of gene panels for different cancer types.
